Skip to content

A clinical trial to study the effects of two drugs, Cadexomer iodine and Povidone iodine in patients with diabetic foot ulcers.

A study on the role and outcome of Povidone Iodine and Cadexomer Iodine in the management of diabetic foot ulcers in a tertiary care center RCT - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088118
Enrollment
100
Registered
2025-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Povidone Iodine: Topical application of ointment on diabetic foot ulcers for treatment at every visit to hospital for wound dressing until healing is achieved - for 2 to 3 weeks as requ

Sponsors

Sathiesh Sundararajan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age group between 35 and 65 years. Patients of both sexes (male and female). Patients with Diabetic Foot Ulcer with adequate arterial blood supply and venous drainage. All the patients with acute or chronic wounds measuring more than 5sq centimeters.

Exclusion criteria

Exclusion criteria: Patients on immunosuppression, corticosteroid, anti- cancer drugs Patients with Severe malnutrition Patients with hepatic dysfunction Patients with thyroid dysfunction Patients with renal dysfunction Patients with extensive burns in the area of treatment

Design outcomes

Primary

MeasureTime frame
Cadexomer Iodine is found to be an effective antiseptic and helps in the healing and formation of granulation tissue in foot ulcers better than Povidone Iodine. It also helps in reducing the size of the ulcer and reducing the amount of discharge from ulcers. Significant improvement in granulation tissue is observed with Cadexomer iodine ointment application compared to povidone iodine ointment. Timepoint: 2-3 weeks

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactSathiesh Sundararajan

Sri Muthukumaran Medical College, Hospital and Reearch Institute

drssathiesh23031983@gmail.com8667077255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026